Precursors in cancer epidemiology: Aligning definition and function

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 4, 2013, Pages 521-527

  Wacholder, Sholom ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COLON CANCER; COLONOSCOPY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONCEPTUAL FRAMEWORK; DNA METHYLATION; EPIGENETICS; FOLLOW UP; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH PROGRAM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYPERLIPIDEMIA; HYPERTENSION; LONGITUDINAL STUDY; PAPILLOMAVIRUS INFECTION; PRECANCER; PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SMOKING; UTERINE CERVIX CANCER;

DISEASE PROGRESSION; HUMANS; NEOPLASMS; PRECANCEROUS CONDITIONS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84876584093     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0084     Document Type: Article

References (39)

1. Franco EL, Rohan TE. Introduction. In:Franco EL, Rohan TE, editors. Cancer precursors: epidemiology, detection and prevention. New York, NY: Springer-Verlag; 2001. p. 1-3.
2. Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, et al. Precancer: a conceptual working definition - results of a Consensus Conference. Cancer Detect Prev 2006;30:387-94. (Pubitemid 44750409)
3. Herrero R, Wacholder S, Rodríguez AC, Solomon D, Gonzalez P, Kreimer AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011;1:408-19.
4. Zhang H, Wacholder S, Qin J, Hildesheim A, Yu K. Improved genetic association tests for an ordinal outcome representing the disease progression process. Genet Epidemiol 2011;35:499-505.
5. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131: 2349-59.
6. Gillison ML, Castellsague X, Chaturvedi AK, et al. Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer. 2013. In press.
7. Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 2013;63: 57-81.
8. Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992;339:576-80.
9. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40. (Pubitemid 19105891)
10. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64. (Pubitemid 23177581)
11. Herrero R, Schiffman MH, Bratti C, Hildesheim A, Balmaceda I, Sherman ME, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997;1:362-75. (Pubitemid 27428425)
12. Schatzkin A, Freedman LS, Dawsey SM, Lanza E. Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst 1994;86:1053-7. (Pubitemid 2124941)
13. Jacobson JS, Neugut AI. Re: Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst 1994;86:1648-9.
14. Bratti MC, Rodríguez AC, Schiffman M, Hildesheim A, Morales J, Alfaro M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica 2004;15:75-89. (Pubitemid 38402500)
15. Rodriguez AC, Burk R, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 2007; 34:494-502. (Pubitemid 46987958)
16. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-7.
17. Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-24.
18. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011;204:94-102.
19. Terry MB, Neugut AI. Cigarette smoking and the colorectal adenomacarcinoma sequence: a hypothesis to explain the paradox. Am J Epidemiol 1998;147:903-10. (Pubitemid 128721158)
20. Poole C. Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. Am J Epidemiol 1999;150:547-51. (Pubitemid 29426897)
21. Potter JD. Invited commentary: old problem, new wrinkles. Am J Epidemiol 1998;147:911-3. (Pubitemid 128721159)
22. Weiss NS. Case-control studies of the efficacy of screening tests designed to prevent the incidence of cancer. Am J Epidemiol 1999; 149:1-4. (Pubitemid 29028855)
23. Applebaum KM, Malloy EJ, Eisen EA. Left truncation, susceptibility, and bias in occupational cohort studies. Epidemiology 2011;22:599-606.
24. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
25. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113:18-25.
26. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51. (Pubitemid 35340782)
27. Wacholder S, Lubin JH, Dosemeci M, Gail MH. Bias despite masked assessment of clinical outcomes when an outcome is defined as one of several component events. Control Clin Trials 1991;12:457-61.
28. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13. (Pubitemid 126450094)
29. Schatzkin A, Freedman LS, Schiffman MH, Dawsey SM. Validation of intermediate end points in cancer research. J Natl Cancer Inst 1990; 82:1746-52.
30. Hartge P, Hayes R, Reding D, Sherman ME, Prorok P, Schiffman M, et al. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial. Am J Obstet Gynecol 2000;183:1232-7.
31. Wacholder S. Chapter 18. Statistical issues in the design and analysis of studies of human papillomavirus and cervical neoplasia. J Natl Cancer Inst Monogr 2003;125-30.
32. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. (Pubitemid 47371147)
33. Wacholder S, Chatterjee N, Caporaso N. Intermediacy and geneenvironment interaction: the example of CHRNA5-A3 region, smoking, nicotine dependence, and lung cancer. J Natl Cancer Inst 2008;100: 1488-91.
34. Wentzensen N, Wacholder S. From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov 2013;3:148-57.
35. Fleming TR, DeGruttola V, DeMets DL. Surrogate endpoints. AIDS Clin Rev 1997;129-43.
36. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309:71-82.
37. Schatzkin A. Intermediate makers is cancer research: theoretical and practical issues in the use of surrogate endpoints. In: Franco EL, Rohan TE, editors. Cancer precursors: epidemiology, detection and prevention. New York: Springer-Verlag; 2001. p. 46-59.
38. Franco E, Rohan T. Cancer precursors: epidemiology, detection and prevention. New York, NY: Springer-Verlag; 2001.
39. Wacholder S. The impact of a prevention effort on the community. Epidemiology 2005;16:1-3. (Pubitemid 40239271)